- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04189614
An Efficacy and Safety Study of Cofetuzumab Pelidotin in Participants With PTK7-Expressing, Recurrent Non-Small Cell Lung Cancer
June 26, 2023 updated by: AbbVie
A Phase 1b Efficacy and Safety Study of Cofetuzumab Pelidotin (ABBV-647, a PTK7-Targeting Antibody Drug Conjugate) in Subjects With PTK7-Expressing, Recurrent Non-Small Cell Lung Cancer
This study is being done to determine the efficacy and safety of cofetuzumab pelidotin in the PTK7-expressing, recurrent non-small cell lung cancer (NSCLC) population.
Study Overview
Status
Active, not recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
65
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Haifa, Israel, 3109601
- Rambam Health Care Campus /ID# 217536
-
Petakh Tikva, Israel, 4941492
- Rabin Medical Center /ID# 217537
-
-
Tel-Aviv
-
Ramat Gan, Tel-Aviv, Israel, 5265601
- The Chaim Sheba Medical Center /ID# 217538
-
-
-
-
Chiba
-
Kashiwa-shi, Chiba, Japan, 277-8577
- National Cancer Center Hospital East /ID# 218537
-
-
Tokyo
-
Chuo-ku, Tokyo, Japan, 104-0045
- National Cancer Center Hospital /ID# 218536
-
-
-
-
-
Seoul, Korea, Republic of, 05505
- Asan Medical Center /ID# 222280
-
Seoul, Korea, Republic of, 06351
- Samsung Medical Center /ID# 222906
-
-
Gyeonggido
-
Seongnam si, Gyeonggido, Korea, Republic of, 13496
- CHA University Bundang Medical Center /ID# 232514
-
-
Seoul Teugbyeolsi
-
Seoul, Seoul Teugbyeolsi, Korea, Republic of, 03722
- Yonsei University Health System Severance Hospital /ID# 222281
-
-
-
-
-
Barcelona, Spain, 08035
- Hospital Universitario Vall d'Hebron /ID# 215729
-
Madrid, Spain, 28040
- Hospital Universitario Fundacion Jimenez Diaz /ID# 215110
-
Madrid, Spain, 28050
- Hospital Universitario HM Sanchinarro /ID# 215102
-
-
-
-
-
Tainan, Taiwan, 704
- National Cheng Kung University Hospital /ID# 222602
-
Taoyuan City, Taiwan, 333
- Linkou Chang Gung Memorial Hospital /ID# 222603
-
-
-
-
Alabama
-
Birmingham, Alabama, United States, 35233
- University of Alabama at Birmingham - Main /ID# 213605
-
-
Arkansas
-
Springdale, Arkansas, United States, 72762
- Highlands Oncology Group, PA /ID# 215383
-
-
California
-
Stanford, California, United States, 94305-2200
- Stanford University School of Med /ID# 213450
-
-
Colorado
-
Aurora, Colorado, United States, 80045
- Univ of Colorado Cancer Center /ID# 215295
-
-
Florida
-
Miami, Florida, United States, 33136-1002
- Sylvester Comprehensive Cancer Center /ID# 216433
-
Tampa, Florida, United States, 33612-9416
- Moffitt Cancer Center /ID# 215101
-
-
Missouri
-
Saint Louis, Missouri, United States, 63110
- Washington University-School of Medicine /ID# 213453
-
-
Ohio
-
Columbus, Ohio, United States, 43210-1257
- The Ohio State University /ID# 211088
-
-
Tennessee
-
Nashville, Tennessee, United States, 37203
- Tennessee Oncology, PLLC /ID# 215326
-
-
Texas
-
Houston, Texas, United States, 77030-3306
- Oncology Consultants /ID# 215932
-
Houston, Texas, United States, 77030
- University of Texas MD Anderson Cancer Center /ID# 215876
-
-
Virginia
-
Fairfax, Virginia, United States, 22031
- Virginia Cancer Specialists - Fairfax /ID# 216427
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Histologically confirmed non-small cell lung cancer (NSCLC) with PTK7-expressing tumor using an immunohistochemistry (IHC) assay previously validated at a designated laboratory
- Recurrent NSCLC that has progressed after treatment with at least the following approved therapies with demonstrated clinical benefit: a platinum-based chemotherapy doublet and an immune checkpoint inhibitor for tumors without targetable genetic alterations; a platinum-based chemotherapy doublet and targeted agent(s) for tumors with targeted genetic alterations
- Received ≤ 2 prior lines of systemic therapy, including no more than 1 line of systemic cytotoxic chemotherapy (≤ 3 prior lines for tumors treated with targeted agent(s) for genetic alterations, including no more than 1 line of systemic chemotherapy)
- Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 1
- Measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1
- Adequate bone marrow, renal, and hepatic function per the protocol
Exclusion Criteria:
- Known uncontrolled metastases to the central nervous system (CNS). Participants with CNS metastases may be eligible provided that definitive therapy has been given, and participants are asymptomatic and off systemic steroids and anticonvulsants used for management of brain metastases for at least 2 weeks prior to the first dose of study drug
- Unresolved clinically significant adverse events Grade ≥ 2 from prior anticancer therapy (with the exception of alopecia or anemia)
- Has clinically significant medical condition(s) as described in the protocol
- Received anticancer therapy including chemotherapy, radiation therapy, immunotherapy, biologic, or any investigational therapy within 28 days prior to the first dose of study drug (no washout period required for participants on EGFR tyrosine kinase inhibitors). Palliative radiation therapy for bone, skin or subcutaneous metastases with 10 fractions or less is not subject to a washout period
- Received anti-cancer herbal therapies within 7 days prior to the first dose of study drug
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Cofetuzumab Pelidotin
Participants will receive 2.8mg/kg of cofetuzumab pelidotin by IV every 3 weeks
|
Intravenous (IV) infusion
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Objective Response Rate (ORR)
Time Frame: Up to approximately 3 years
|
ORR assessed by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 criteria and defined as the percentage of participants with confirmed complete response (CR) or confirmed partial response (PR).
|
Up to approximately 3 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Duration of Response (DOR)
Time Frame: Up to approximately 3 years
|
DOR is defined as the time from the participant's initial response (CR or PR) to the first occurrence of radiographic progression or death from any cause.
|
Up to approximately 3 years
|
Progression Free Survival (PFS)
Time Frame: Up to approximately 3 years
|
PFS is defined as the time from the participant's first dose of study drug until radiographic progression or death from any cause.
|
Up to approximately 3 years
|
Overall Survival (OS)
Time Frame: Up to approximately 3 years
|
OS is defined as the time from the participant's first dose of study drug until death from any cause.
|
Up to approximately 3 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
February 13, 2020
Primary Completion (Estimated)
February 13, 2024
Study Completion (Estimated)
February 13, 2024
Study Registration Dates
First Submitted
December 5, 2019
First Submitted That Met QC Criteria
December 5, 2019
First Posted (Actual)
December 6, 2019
Study Record Updates
Last Update Posted (Actual)
June 27, 2023
Last Update Submitted That Met QC Criteria
June 26, 2023
Last Verified
June 1, 2023
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- M19-611
- 2019-003472-39 (EudraCT Number)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cancer
-
University of Michigan Rogel Cancer CenterRecruitingCancer Liver | Cancer Brain | Cancer Head &Neck | Cancer PelvisUnited States
-
Cellworks Group Inc.RecruitingCancer | Relapsed Cancer | Refractory CancerUnited States
-
UNC Lineberger Comprehensive Cancer CenterHyundai Hope On WheelsRecruitingCancer | Pediatric Cancer | Survivorship | Cancer MetastaticUnited States
-
Vanderbilt-Ingram Cancer CenterNational Institutes of Health (NIH)Active, not recruitingAdvanced Cancer | Relapsed Cancer | Refractory CancerUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)CompletedStage III Pancreatic Cancer | Stage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage IV Gastric Cancer | Stage IVA Colorectal Cancer | Stage IVA Pancreatic Cancer | Stage IVB Colorectal Cancer | Stage IVB Pancreatic Cancer | Stage IIIA Gastric Cancer | Stage IIIB Gastric Cancer | Stage IIIC Gastric... and other conditionsUnited States
-
MiRXES Pte LtdRecruitingBreast Cancer | Gastric Cancer | Colorectal Cancer | Pancreatic Cancer | Esophageal Cancer | Ovarian Cancer | Prostate Cancer | Thoracic Cancer | Liver CancerSingapore
-
Sidney Kimmel Cancer Center at Thomas Jefferson...CompletedStage I Breast Cancer | Stage I Uterine Corpus Cancer | Stage II Uterine Corpus Cancer | Stage III Uterine Corpus Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage... and other conditionsUnited States
-
Massachusetts General HospitalNational Comprehensive Cancer NetworkCompletedGastric Cancer | Pancreatic Cancer | Esophageal Cancer | Rectal Cancer | Colon Cancer | Hepatobiliary CancerUnited States
-
University of California, San FranciscoBristol-Myers Squibb; PfizerTerminatedStage IIIA Rectal Cancer | Stage IIIB Rectal Cancer | Stage IIIC Rectal Cancer | Metastatic Colorectal Adenocarcinoma | Metastatic Colon Adenocarcinoma | Metastatic Rectal Adenocarcinoma | Stage IIIA Colon Cancer | Stage IIIB Colon Cancer | Stage IIIC Colon Cancer | Stage IV Colon Cancer | Stage IV Rectal... and other conditionsUnited States
-
Johns Hopkins UniversityNational Cancer Institute (NCI); National Institute on Minority Health and...Enrolling by invitationCancer | Advanced Cancer | End Stage Cancer | MalignancyUnited States